Truscreen Group Limited’s (ASX:TRU) China distributor, Beijing Siweixiantai Tech Co. Ltd (SWXT), has placed an order for 40 TruScreen cervical cancer screening devices for installation into China’s growing public Health Check Sector. Delivery is expected in April 2023.
Following long COVID delays the initial installation of TruScreen into the public Health Check Centre within The People’s Liberation Army General Hospital, one of the leading health check centres in the country was completed in February 2023. This is the first installation into a public Health Check Centre and SWXT is expecting rapid growth in the year ahead.
TruScreen won the tender in February 2023 for Affiliated Hospital of Nantong University in Nantong, Jiangsu Province. The hospital is one of the largest in the province and is highly regarded in North Jiangsu. The head of its Obstetric and Gynecologic Department is the current Chair of COGA Jiangsu Provincial branch (see NZX/ASX announcement dated 5 April 2022).
China, after the COVID lockdown years, is now seeing a strong pipeline of significant growth opportunities. This includes seven hospital tenders won with 13 installations pending, 23 hospitals where TruScreen has been approved and waiting for tender outcomes, and 78 hospitals where Obstetric and Gynecologic Department acceptance have been received and are waiting for the next stage of hospital approval.
TruScreen has developed an AI-enabled device that can detect precancerous and cancerous cervical changes in real-time via optical and electrical measurements of cervical tissue. Unlike many cervical screening technologies that have only triage/adjunct functionality, the TruScreen device is registered as a primary screening tool.
TruScreen’s cervical screening technology effectively resolves many of the ongoing issues with conventional cytology, including failed samples, poor patient follow-up, patient discomfort, and the need for supporting laboratory infrastructure.
The device is CE-marked, meaning it meets EU safety, health and environmental protection standards required for sale and use throughout Europe. It is also National Medical Products Administration approved for sale in China. In 2021, TruScreen established a manufacturing facility in China for devices marketed and sold in China.
TruScreen is currently targeting product sales to a range of low and middle-income countries, including China, Mexico, Vietnam, Russia, Zimbabwe and Saudi Arabia, where no large-scale cervical cancer screening programmes and infrastructure are currently in place. By doing so, the Company hopes to help improve the health and wellbeing of women worldwide.